Abstract 782P
Background
Acute myeloid leukemia (AML) is a hematologic malignancy that exhibits clinical heterogeneity. The response to chemotherapy and survival outcome of AML is determined by cytogenetic and molecular genetic alterations. Antigen-expression profiles have been discovered as surrogates for certain leukemic genotypes. According to prior studies, patients with AML who express CD25 and CD123 are more likely to have worse outcomes.
Methods
This is a prospective study of 70 patients with newly diagnosed patients with AML treated with induction chemotherapy at Regional Cancer Centre, Thiruvananthapuram from 01-01-22 to 31-12-22. Flow cytometry in the bone marrow aspiration samples were done to determine the expression of CD25 and CD123 markers. Remission status was assessed at the end of induction and consolidation. Remission status after induction chemotherapy was correlated with the expression of CD25 and CD123. Event-free survival and overall survival were also correlated with CD25 and CD123 expression.
Results
In this study, we recruited 70 patients. The median age of the study group was 44 years. There were 32 males and 38 females. Thirty-two (54%) patients achieved complete remission following induction. Among the 70 patients, 18% were CD25 positive, and 94% were CD123 positive. When CD25 expression was correlated with post-induction response, 46% of patients who express CD25 marker attained CR where as 56% of patients who were CD25 negative achieved CR (p=0.55). CD123 expression was seen in 94%, of which 53% of patients attained CR (p=0.62). In this study, expression of CD25 and CD123 in AML patients doesn’t have correlation with post-induction remission status, event-free survival and overall survival.
Conclusions
In our study group, 18% were CD 25-positive and 94% were CD123 positive. Expression of CD25 and CD123 in AML patients didn’t show correlation with post-induction remission status, event-free survival and overall survival.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
G. Narayanan.
Funding
Regional Cancer Centre-Thiruvananthapuram, India.
Disclosure
All authors have declared no conflicts of interest.